Robert Wechsler-Reya
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (2)
Deregulation of neuroblastoma-derived myc (N-myc) is a leading cause of malignant brain tumors in children. To target N-myc-driven medulloblastoma, most research has focused on identifying genomic alterations or on the analysis of the medulloblastoma transcriptome. Here, we have broadly characterized the translatome of medulloblastoma and shown that N-myc unexpectedly drives selective translation of transcripts that promote protein homeostasis. Cancer cells are constantly exposed to proteotoxic stress associated with alterations in protein production or folding. It remains poorly understood how cancers cope with proteotoxic stress to promote their growth. Here, our data revealed that N-myc regulates the expression of specific components (∼5%) of the protein folding machinery at the translational level through the major cap binding protein, eukaryotic initiation factor eIF4E. Reducing eIF4E levels in mouse models of medulloblastoma blocked tumorigenesis. Importantly, targeting Hsp70, a protein folding chaperone translationally regulated by N-myc, suppressed tumor growth in mouse and human medulloblastoma xenograft models. These findings reveal a previously hidden molecular program that promotes medulloblastoma formation and identify new therapies that may have impact in the clinic. Significance: Translatome analysis in medulloblastoma shows that N-myc drives selective translation of transcripts that promote protein homeostasis and that represent new therapeutic vulnerabilities.
Year:
2025
Diffuse Midline Gliomas (DMGs) are universally fatal, primarily pediatric malignancies affecting the midline structures of the central nervous system. Despite decades of clinical trials, treatment remains limited to palliative radiation therapy. A major challenge is the coexistence of molecularly distinct malignant cell states with potentially orthogonal drug sensitivities. To address this challenge, we leveraged established network-based methodologies to elucidate Master Regulator (MR) proteins representing mechanistic, non-oncogene dependencies of seven coexisting subpopulations identified by single-cell analysis—whose enrichment in essential genes was validated by pooled CRISPR/Cas9 screens. Perturbational profiles of 372 clinically relevant drugs helped identify those able to invert the activity of subpopulation-specific MRs for follow-up in vivo validation. While individual drugs predicted to target individual subpopulations—including avapritinib, larotrectinib, and ruxolitinib—produced only modest tumor growth reduction in orthotopic models, systemic co-administration induced significant survival extension, making this approach a valuable contribution to the rational design of combination therapy.
Year:
2024
Collaborators (10)
Davide Ruggero
Professor
University of California
Robyn Gartrell
Assistant Professor of Pediatrics in Division of Pediatric Hematology/Oncology/SCT
Johns Hopkins University School of Medicine
Duygu Kuzuoglu Ozturk
Assistant Prof
Sabancı University
Hong-Jian Wei
Research Assistant Professor
Virginia Tech
Andrea Califano
Columbia University Irving Medical Center
Jason E. Gestwicki
Professor
University of California, San Francisco
Miller Huang
Assistant Professor
University of Southern California
Joanna J. Phillips
Profesor
University of California, San Francisco
Theophilos Tzaridis
Sanford Burnham Prebys Medical Discovery Institute
William A. Weiss
Director of outpatient child neurology
University of California
Make your next move.
Prepare your application
Review drafts before you send them.